Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 229 across all filing types
Latest filing 2026-06-15 Regulatory Filings
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis – supports phase 3 design, regulatory interactions, and partnering
Regulatory Filings Classification · 95% confidence The document is a press release from SynAct Pharma dated June 15, 2026, reporting positive clinical trial results from the Phase 2b ADVANCE study on resomelagon in Rheumatoid Arthritis. It discusses study design, clinical effectiveness, safety profile, and implications for future phases, as well as upcoming webcast and partnering activities. It contains detailed study data and interpretation but is presented as a press release rather than a formal financial or regulatory filing. It does not contain audited financial information or quarterly results and is not a full Annual or Interim report. Nor is it an earnings release. The content is primarily clinical trial results and business development update. This fits best under Regulatory Filings (RNS) as it is a corporate announcement on clinical trial progress and company business development but not a financial or governance report or notice of meeting results. The length (8760 characters) and press release nature confirm it is not a brief announcement or a lengthy report.
2026-06-15 English
Fas 2b-studien ADVANCE visar positiva effekter av resomelagon vid reumatoid artrit – stöder fas 3-design, regulatoriska interaktioner och partnerskap
Regulatory Filings Classification · 95% confidence The document is a press release dated June 15, 2026, from SynAct Pharma announcing positive clinical trial results (Phase 2b study ADVANCE) for their drug candidate resomelagon in rheumatoid arthritis. The content details study design, efficacy outcomes, safety profile, and future plans for regulatory interactions, phase 3 design, and partnership development. The document also mentions a webcast presentation and plans to share a presentation on their website. There are no full financial statements or accounting details presented. The document length is under 10,000 characters, and it is clearly an announcement of clinical trial results and business updates rather than a full investor presentation or regulatory form. It does not qualify as an Earnings Release since it lacks key financial result highlights, nor is it a Management Discussion/Analysis or Annual Report. The primary focus is on clinical study results and related business development news. This aligns best with the category of Regulatory Filings (RNS), used for general regulatory announcements and informational press releases that do not fit other specific financial reporting categories.
2026-06-15 Swedish
Kommuniké från årsstämma 2026 i SynAct Pharma AB
AGM Information Classification · 88% confidence The document is a press release summarizing the main decisions taken at the 2026 Annual General Meeting (AGM) of SynAct Pharma AB, including adoption of financial statements, discharge from liability, board and auditor elections, remuneration approvals, and authorization for share issuances. It is a communiqué from the AGM, not the full annual report or any other standalone report. Therefore, it should be classified as AGM Information (AGM-R).
2026-06-11 Swedish
Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release reporting the official resolutions adopted by shareholders at the 2026 Annual General Meeting, including vote outcomes on financial statements, board and auditor elections, remuneration approvals, and authorisations. This aligns with the Declaration of Voting Results & Voting Rights Announcements category.
2026-06-11 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Delårsrapport Januari – Mars 2026” and contains a full set of interim financial statements (income statement, balance sheet, cash flow, equity changes, notes), management commentary, Q&A with executives, operational highlights, and KPMG-style management assurance. It is a comprehensive quarterly report for the first quarter of 2026, not merely an announcement or summary. Under the definitions, this clearly qualifies as an Interim/Quarterly Report. Q1 2026
2026-05-27 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Interim Report January – March 2026” for SynAct Pharma AB, covering Q1 financial performance with actual income statement, balance sheet, cash flows, notes, CEO commentary, Q&A and other substantive financial data. It is a full interim/quarterly report rather than a brief announcement or transcript. Therefore it fits the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-27 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.